Dataset: Inhibition of BET bromodomain proteins as a therapeutic approach in prostate cancer

We analyzed transcriptional changes in 4 prostate cancer cell lines following treatment with the BET inhibitor I-BET762 using Affymetrix Human Genome U133 Plus 2.0 Arrays. Four prostate cancer cell lines (NCI-H660, VCaP, LNCaP, PC-3) were treated with DMSO (control) or I-BET762 at 0.5uM or 10uM concentrations for 24 hours. Two biological replicates are included for each treatment group.

Species:

human

Samples:

24

Source:

E-GEOD-56352

PubMed:

24293458

Updated:

Dec.12, 2014

Registered:

Jul.11, 2014